See more : T.T. Limited (TTL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of MoonLake Immunotherapeutics (MLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MoonLake Immunotherapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asahi Rubber Inc. (5162.T) Income Statement Analysis – Financial Results
- ComfortDelGro Corporation Limited (CDGLF) Income Statement Analysis – Financial Results
- Changhong Huayi Compressor Co., Ltd. (000404.SZ) Income Statement Analysis – Financial Results
- GENUS PRIME INFRA LIMITED (GENUSPRIME.BO) Income Statement Analysis – Financial Results
- Amesite Inc. (AMST) Income Statement Analysis – Financial Results
MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.16K | 12.36K | 4.97K | 0.00 |
| Gross Profit | -13.16K | -12.36K | -4.97K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.80M | 42.05M | 35.52M | 0.00 |
| General & Administrative | 22.32M | 23.01M | 21.66M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 18.03M | 0.00 |
| SG&A | 22.32M | 23.01M | 18.05M | 105.76K |
| Other Expenses | 0.00 | 591.73K | 0.00 | 0.00 |
| Operating Expenses | 54.12M | 65.06M | 53.57M | 105.76K |
| Cost & Expenses | 54.12M | 65.06M | 53.58M | 105.76K |
| Interest Income | 0.00 | 0.00 | 0.00 | 14.92K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.16K | 12.36K | 4.97K | 206.30K |
| EBITDA | -54.11M | -65.05M | -53.63M | -90.84K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -54.12M | -65.06M | -53.58M | -105.76K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 591.73K | 10.65M | 14.92K |
| Income Before Tax | -43.98M | -64.47M | -53.64M | -90.84K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.39K | 36.37K | 4.76K | -206.30K |
| Net Income | -36.01M | -64.51M | -53.64M | -90.84K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.73 | -2.20 | -6.84 | -0.01 |
| EPS Diluted | -0.73 | -2.20 | -6.84 | -0.01 |
| Weighted Avg Shares Out | 49.12M | 29.36M | 7.84M | 14.81M |
| Weighted Avg Shares Out (Dil) | 49.12M | 29.36M | 7.84M | 14.81M |
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains in CLLS +16.8%...
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
Strong Mid-Cap Insider Buys: Q2 2023
We continue with our recurring series based on analyzing mid-cap stocks that have enjoyed periods unusual insider interest during the second quarter of the year. An overwhelming trend of bank insiders buying stakes in the regional banking sector still pursues,...
Exclusive: MoonLake Immunotherapeutics explores sale-sources
MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week
Earlier this week, MoonLake Immunotherapeutics announced positive mid-stage results for its hidradenitis suppurativa treatment. The therapy could become the standard of care for this chronic skin condition.
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical stage biotech MoonLake Immunotherapeutics AG NASDAQ: MLTX shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies that can bind to smaller targets.
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today
Several analysts dramatically increased their price targets on the biotech. This followed very strong clinical trial results for an investigational treatment for a skin affliction.
Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday
MoonLake specializes in treating inflammatory conditions. It presented positive Phase 2 trials regarding its lead therapy, sonelokimab.
Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today?
MoonLake Immunotherapeutics (NASDAQ: MLTX ) stock is taking off on Monday after reporting positive results from a Phase 2 clinical trial. Those results come from the company's clinical trial evaluating the efficacy and safety of Nanobody sonelokimab.
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
MoonLake Immunotherapeutics (MLTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...
Source: https://incomestatements.info
Category: Stock Reports